Tarsus Pharmaceuticals (TARS) Other Non Operating Income (2019 - 2026)
Tarsus Pharmaceuticals (TARS) recorded quarterly Other Non Operating Income of -$87000.0 in Q1 2026, down 17.57% quarter-over-quarter from -$74000.0 in Q4 2025, and down 7.41% on a YoY basis from -$93960.0 in Q1 2025.
Tarsus Pharmaceuticals (TARS) Other Non Operating Income (2019 - 2026) Analysis & Trends
Tarsus Pharmaceuticals' Other Non Operating Income history runs 7 years deep, the most recent figure standing at -$87000.0 for Q1 2026.
- In Q1 2026, Other Non Operating Income fell 7.41% year-over-year to -$87000.0; the TTM figure through Mar 2026 stood at -$63000.0 (up 96.5% YoY), while the FY2025 annual figure was -$202000.0, up 89.37% from the prior year.
- Other Non Operating Income was -$87000.0 for Q1 2026 at Tarsus Pharmaceuticals, down from -$74000.0 in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $606000.0 in Q4 2022 to a low of -$1.7 million in Q4 2024.
- Historically, Other Non Operating Income has averaged -$66437.5 across 5 years, with a median of -$12000.0 in 2022.
- The sharpest annual moves came in 2022 and 2024: Other Non Operating Income jumped 371.79% in 2022, then plunged 964.71% in 2024.
- A 5-year view of Other Non Operating Income shows it stood at $606000.0 in 2022, then plunged by 54.79% to $274000.0 in 2023, then plunged by 728.1% to -$1.7 million in 2024, then jumped by 95.7% to -$74000.0 in 2025, then decreased by 17.57% to -$87000.0 in 2026.
- The last three Other Non Operating Income figures came in at -$87000.0 (Q1 2026), -$74000.0 (Q4 2025), and $98000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Tarsus Pharmaceuticals | 2.71 Bn | 2.61 Bn | 152.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -87,000.00 |
| Dec 31, 2025 | -74,000.00 |
| Sep 30, 2025 | 98,000.00 |
| Mar 31, 2025 | -81,000.00 |
| Dec 31, 2024 | -1.72 Mn |
| Sep 30, 2024 | 67,000.00 |
| Jun 30, 2024 | -65,000.00 |
| Mar 31, 2024 | -181,000.00 |
| Dec 31, 2023 | 274,000.00 |
| Sep 30, 2023 | -36,000.00 |
| Jun 30, 2023 | 18,000.00 |
| Mar 31, 2023 | -17,000.00 |
| Dec 31, 2022 | 606,000.00 |
| Sep 30, 2022 | -7,000.00 |
| Jun 30, 2022 | 106,000.00 |
| Mar 31, 2022 | 37,000.00 |
| Dec 31, 2021 | -919,000.00 |
| Sep 30, 2021 | -346,000.00 |
| Jun 30, 2021 | -39,000.00 |
| Mar 31, 2021 | -34,000.00 |